🔥NEOpredict-Lung: Neoadjuvant nivolumab with or without relatlimab (anti-LAG-3) in resectable NSCLC
🎙️Dr. Martin Schuler Nature Medicine
🎯DFS%12mo: 93% in combination
✅Phase II
✅Primary: Feasibility of surgery
✅NCT04205552
#LCSM OncoAlert
nature.com/articles/s4159…

The monarchE trial 🦋
➡️ when required, dose reduction, improve tolerability maximize treatment adherence,maintain the benefit from adjuvant abemaciclib in combination with endocrine therapy for high-risk HR+, HER2- EBC.
⁦OncoAlert⁩ #OncoAlertAf nature.com/articles/s4152…

Cancer diagnoses among Black adolescents and young adults are associated with greater psychological distress within an already vulnerable population.

acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn…

OncoAlert John M. Salsman #ayacsm

Do not Miss the #ASCOPlennarySeries TODAY
by our collaborators🚨 at ASCO 🌐
4/30/24 at 3pm EST (NY)🇺🇸

'Glecirasib Shows Promise in Treating Patients w/ #NSCLC 🫁w/ KRAS G12C Mutation🧬

Link: meetings.asco.org/asco-plenary-s…

panelists
Melissa L. Johnson, Yuankai Shi, Stephen V Liu, MD…

🎉 Huge congratulations to the team for hard work and dedication!
Brilliant job Coskun YAZGAN Erman Akkus Emre Yekedüz !
OncoAlert Advanced Prostate Cancer Consensus Conference Prostate Cancer Foundation Ankara Üniversitesi Ankara Üniversitesi Tıp Fakültesi
sciencedirect.com/science/articl…

Alternative approaches to risk–benefit balancing in immunotherapy

🔹️Are proactive approaches like prophylactic tocilizumab appropriate to reduce side effects?

🔹️We know that there isn't a linear dose-response relationship in anti-PD1 and anti-PDL1 therapies, so can we…

💫🌟🚨Relevant OncoAlert message🌟💫

If you are attending #ASCO24 don’t forget to register to the 🚨 OncoAlert 5K walk/run. June 1st, 7 AM. Start Hyatt Regency at McCormick Place, Chicago!
⬇️⬇️⬇️

They are back!!
The #ASCOPlennarySeries TOMORROW 4/30, 3pm ET
Kudos to our Collaborators at ASCO ‼️

'Glecirasib Shows Promise in Treating Patients w/ #NSCLC 🫁w/ KRAS G12C Mutation🧬'

panelists Melissa L. Johnson , Yuankai Shi, Stephen V Liu, MD Julia Rotow MD #LungCancer

Abstract:…

Exciting that a new option is on the horizon. Magnitude of benefit, patient reported outcomes, adverse-events, and understanding the role (if any) of HER2-low as a biomarker will shape the place T-DXd ultimately takes for HR+ HER2-low or ultralow MBC in the lineup.
#DB06 #bcsm

Gefitinib + chemotherapy combo continues to show ⬆️PFS & OS at 5y of follow-up vs gefitinib monotherapy in #EGFR + #NSCLC .
5-year OS: 13% vs 4.4% (HR, 0.58). 5-year PFS: 6.7% vs 1.7% (HR, 0.53). Implications for countries with limited access to 3rd gen TKIs 🚨🚨OncoAlert #LCSM

💫🌟  #APCCC24 Día 3️⃣ Aspectos destacados 🌟💫
Advanced Prostate Cancer Consensus Conference OncoAlert OncoReporte
silke gillessen aurelius omlin
1. 🧬 Dr. Heather Cheng - Urgencia de las pruebas de la línea germinal en el cáncer de próstata avanzado.  Detectar mutaciones para abrir opciones de tratamiento…

💫🌟 #APCCC24
Día 1️⃣ 🌟🔝🔝🔝Aspectos destacados: Navegando por el panorama cambiante del cáncer de próstata metastásico sensible a hormonas (mHSPC).
Advanced Prostate Cancer Consensus Conference OncoAlert OncoReporte silke gillessen
aurelius omlin
Ideas clave de las conversaciones:
🧬 El Dr. Matthew Smith…

Te invitamos a este podcast de GU Cast | Urology podcast! , Uromigos y OncoAlert grabado en Lugano durante #APCCC24

5⃣ amigos, 4⃣microfonos, 1⃣camara y MUCHAS SONRISAS!!!

Declan Murphy🇦🇺
Renu Eapen🇦🇺
Brian Rini, MD🇺🇸
Tom Powles 🇬🇧
Gil Morgan, MD🇺🇸

✅✅✅A must-read review in Nature Reviews Urology on liver metastasis of prostate cancer!

✨From biology to the clinic‼️

➡️Liver metastases from prostate cancer are found in up to 25% of patients with advanced disease based on autopsy studies, and in 3–10% of those with metastatic…

Thank you very much aurelius omlin and kudos to you, silke gillessen and the entire Advanced Prostate Cancer Consensus Conference team for having OncoAlert 🚨involved. An honour and a pleasure to be able to for part of this AMAZING meeting in Lugano!

Phase 1 study of ARO-HIF2 shows promise in targeting HIF2α for ccRCC treatment, achieving tumor growth inhibition in a subset of patients. Challenges include neurotoxicity & low response rate.
James Brugarolas Clinical Cancer Research OncoAlert #Cancer #oncology Katy Beckermann Brian Rini, MD…

💫🌟  #APCCC24 Day 3️⃣ Highlights 🌟💫
Advanced Prostate Cancer Consensus Conference OncoAlert
silke gillessen aurelius omlin
1. 🧬 Dr. Heather Cheng - Urgency of germline testing in advanced prostate cancer. Detecting mutations to open up personalized treatment options. 🔬 #GeneticsInCancer

2. 🌐 Dr. Ana Aparicio -…

The OncoAlert Network would like to thank our faculty for their amazing coverage of #APCCC24

We highly encourage our colleagues to follow them:
silke gillessen & aurelius omlin 🇨🇭
Neeraj Agarwal, MD, FASCO 🇺🇸
Dra. María Natalia Gandur Quiroga 🇹🇷
Yüksel Ürün 🇦🇷

Best,
The Network🚨

Para pacientes fit a QT y con criterios para LU-PSMA y puedan acceder al tto la estrategia es⁉️
🇦🇷UrooncoArgentina #APCCC24 OncoAlert Advanced Prostate Cancer Consensus Conference Uromigos GU Cast | Urology podcast! silke gillessen Urooncologia.arg EAU Edu Platform UROONCO Urooncologia.arg Neeraj Agarwal, MD, FASCO Asociación Argentina de Oncología Clínica (AAOC) UroTarget